Literature DB >> 15455371

Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.

Ting-Chih Cheng1, Shou-Tung Chen, Chiun-Sheng Huang, Yi-Ping Fu, Jyh-Cherng Yu, Chun-Wen Cheng, Pei-Ei Wu, Chen-Yang Shen.   

Abstract

Estrogen has been suggested to trigger breast cancer development via an initiating mechanism involving its metabolite, catechol estrogen (CE). To examine this hypothesis, we carried out a multigenic case-control study of 469 incident breast cancer patients and 740 healthy controls to define the role of important genes involved in the different metabolic steps that protect against the potentially harmful effects of CE metabolism. We studied the 3 genes involved in CE detoxification by conjugation reactions involving methylation (catechol-O-methyltransferase, COMT), sulfation (sulfotransferase 1A1, SULT1A1), or glucuronidation (UDP-glucuronosyltransferase 1A1, UGT1A1), one (manganese superoxide dismutase, MnSOD) involved in protection against reactive oxidative species-mediated oxidation during the conversion of CE-semiquinone (CE-SQ) to CE-quinone (CE-Q), and 2 of the glutathione S-transferase superfamily, GSTM1 and GSTT1, involved in CE-Q metabolism. Support for this hypothesis came from the observations that (i) there was a trend toward an increased risk of breast cancer in women harboring a greater number of putative high-risk genotypes of these genes (p < 0.05); (ii) this association was stronger and more significant in those women who were more susceptible to estrogen [no history of pregnancy or older (> or =26 years) at first full-term pregnancy (FFTP)]; and (iii) the risks associated with having one or more high-risk genotypes were not the same in women having experienced different menarche-to-FFTP intervals, being more significant in women having been exposed to estrogen for a longer period (> or =12 years) before FFTP. Furthermore, because CE-Q can attack DNA, leading to the formation of double-strand breaks (DSB), we examined whether the relationship between cancer risk and the genotypic polymorphism of CE-metabolizing genes was modified by the genotypes of DSB repair genes, and found that a joint effect of CE-metabolizing genes and one of the two DSB repair pathways, the homologous recombination pathway, was significantly associated with breast cancer development. Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15455371     DOI: 10.1002/ijc.20630

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

Review 1.  GSTT1 polymorphism and breast cancer risk in the Chinese population: an updated meta-analysis and review.

Authors:  Zhang-Sheng Xiao; Yun Li; Yan-Li Guan; Jia-Gen Li
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 2.  Superoxide dismutase 2 gene and cancer risk: evidence from an updated meta-analysis.

Authors:  Sang Wook Kang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation.

Authors:  Miriam S Udler; Kerstin B Meyer; Karen A Pooley; Eric Karlins; Jeffery P Struewing; Jinghui Zhang; David R Doody; Stewart MacArthur; Jonathan Tyrer; Paul D Pharoah; Robert Luben; Leslie Bernstein; Laurence N Kolonel; Brian E Henderson; Loic Le Marchand; Giske Ursin; Michael F Press; Paul Brennan; Suleeporn Sangrajrang; Valerie Gaborieau; Fabrice Odefrey; Chen-Yang Shen; Pei-Ei Wu; Hui-Chun Wang; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; Bruce A J Ponder; Christopher A Haiman; Kathleen E Malone; Alison M Dunning; Elaine A Ostrander; Douglas F Easton
Journal:  Hum Mol Genet       Date:  2009-02-17       Impact factor: 6.150

4.  The Val158Met polymorphism in the COMT gene is associated with increased cancer risks in Chinese population.

Authors:  Can Tian; Liping Liu; Xiaohong Yang; Hui Wu; Quchang Ouyang
Journal:  Tumour Biol       Date:  2013-12-05

5.  Association between the COMT Val158Met polymorphism and breast cancer risk: a meta-analysis of 30,199 cases and 38,922 controls.

Authors:  Xiao-Feng He; Wu Wei; Shao-Xia Li; Jiao Su; Ying Zhang; Xiang-Hua Ye; Yi Liu; Wei Wang
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

6.  There is no relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival.

Authors:  Chengdi Wang; Yang Liu; Jian Zhou; Lei Ye; Nan Chen; Min Zhu; Yulin Ji
Journal:  Mol Clin Oncol       Date:  2017-08-14

7.  A polymorphism in the promoter region of Ku70/XRCC6, associated with breast cancer risk and oestrogen exposure.

Authors:  Petra Willems; Kim De Ruyck; Rudy Van den Broecke; Amin Makar; Gianpaolo Perletti; Hubert Thierens; Anne Vral
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-15       Impact factor: 4.553

8.  Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue.

Authors:  Yiwei Jiang; Liheng Zhou; Tingting Yan; Zhenzhou Shen; Zhimin Shao; Jinsong Lu
Journal:  J Exp Clin Cancer Res       Date:  2010-07-21

9.  Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk.

Authors:  Kerryn W Reding; Noel S Weiss; Chu Chen; Christopher I Li; Christopher S Carlson; Hui-Wen Wilkerson; Federico M Farin; Kenneth E Thummel; Janet R Daling; Kathleen E Malone
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

10.  Bisphenol-A glucuronidation in human liver and breast: identification of UDP-glucuronosyltransferases (UGTs) and influence of genetic polymorphisms.

Authors:  Christina M Street; Zhaohui Zhu; Moshe Finel; Michael H Court
Journal:  Xenobiotica       Date:  2016-03-21       Impact factor: 1.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.